India should make a strategic investment in vaccine manufacturers
Despite the current hype, vaccines aren’t a hugely profitable area of pharmaceuticals
April 15, 2021 / 08:30 AM IST
The outlook for the emerging market is uncertain, partly due to a large population base and low availability of vaccines. (File Image)
Adar Poonawalla, the chief executive officer of Serum Institute of India (SII), has said his company needs Rs 3000 crore to ramp up its vaccine manufacturing capacity at this critical juncture. While it is not known if Krishna Ella, chairman of Bharat Biotech Ltd. (BBL), the other major vaccine producer in the country, has expressed similar views, it is safe to assume that the Hyderabad-based manufacturer too could use the extra funding. Nor is it an unusual request. Many...